How Fast Does Wegovy Work? A Week-by-Week Timeline From First Dose to Maintenance

Key Takeaways

• Wegovy starts working pharmacologically within hours of the first dose, but appetite suppression usually becomes noticeable in week 1 to 2.
• Visible weight loss typically appears between week 4 and 8, once the dose has been escalated past 0.5 mg.
• The full 2.4 mg maintenance dose is reached at week 17 under the standard titration schedule.
• In the STEP 1 trial, the average patient lost 5.9% of body weight by week 12 and 14.9% by week 68 (Wilding et al., NEJM 2021).
• Patients who do not lose at least 5% of body weight by week 16 to 20 at the maintenance dose are unlikely to be strong responders.
• Speed of response varies. Genetics, baseline metabolic rate, diet adherence, and sleep all change the curve.

Direct answer (40-60 words)

Wegovy starts suppressing appetite within hours of the first injection, but most patients notice reduced hunger by week 1 to 2 and visible weight loss by week 4 to 8. The full 2.4 mg maintenance dose is reached at week 17. Average weight loss is 5.9% at 12 weeks and 14.9% at 68 weeks (Wilding et al., NEJM 2021).

Table of contents

1. The 30-second answer
2. The pharmacology: what happens after your first injection
3. The standard Wegovy titration schedule
4. Week-by-week: what to expect from week 1 to week 68
5. The STEP 1 trial: published weight-loss curves
6. Why some patients respond faster than others
7. The 16-week response check
8. When Wegovy is "not working" yet vs not working at all
9. How food, sleep, and exercise change the timeline
10. FAQ
11. Sources
12. Footer disclaimers

The pharmacology: what happens after your first injection

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly GLP-1 receptor agonist made by Novo Nordisk. After a subcutaneous injection, semaglutide reaches peak plasma concentration in 1 to 3 days and has a half-life of about 7 days, which is what allows once-weekly dosing (Lau et al., J Med Chem 2015).

The active ingredient binds to GLP-1 receptors in three main places:

1. The pancreas, where it boosts glucose-dependent insulin release.
2. The stomach, where it slows gastric emptying.
3. The hypothalamus, where it reduces appetite and food reward signaling.

The hypothalamic effect is the one most patients notice first. Brain receptors don't wait for steady-state plasma levels. Within hours of the first injection, semaglutide is already crossing into central appetite circuits and dampening hunger signaling. That's why some patients describe a "quiet stomach" feeling on day 1 or 2 of their first dose.

The reason visible weight loss takes weeks rather than days is dose. The starting dose is 0.25 mg, far below the 2.4 mg maintenance level. At the starter dose the appetite effect is mild for most patients. Real-world weight loss accelerates only after the third or fourth dose escalation.

The standard Wegovy titration schedule

Novo Nordisk's prescribing information recommends a 5-step titration over 16 weeks before reaching the full maintenance dose:

The titration exists to reduce nausea, vomiting, and other GI side effects that scale with dose. Skipping ahead causes worse side effects and higher discontinuation rates without speeding weight loss in any meaningful way.

Some providers extend a step by an extra 2 to 4 weeks if a patient has tolerability issues. Slowing the titration usually does not reduce final weight loss. It just shifts the curve to the right.

Week-by-week: what to expect from week 1 to week 68

Week 1 (0.25 mg). Most patients feel a mild reduction in appetite within 1 to 3 days. Some get nausea, especially after the first 2 or 3 doses. Weight loss in week 1 is usually 0 to 2 pounds, and most of it is water from reduced food intake rather than fat loss.

Weeks 2 to 4 (0.25 mg). Hunger continues to decrease. Portion sizes drop. Many patients report 3 to 6 pounds of weight loss by the end of week 4. The scale moves slowly because the dose is small, but the appetite changes are setting up the months that follow.

Weeks 5 to 8 (0.5 mg). Side effects sometimes intensify in the first 7 to 10 days after the dose increase. Appetite suppression deepens. Average weight loss by end of week 8 is 4 to 7 pounds, or about 2 to 4% of body weight. Visible body changes are still subtle for most patients.

Weeks 9 to 12 (1.0 mg). This is the inflection point. Most patients report meaningful changes in clothing fit, energy, and food preferences. Average weight loss by week 12 in the STEP 1 trial was 5.9% of body weight (Wilding et al., NEJM 2021), which is roughly 13 to 18 pounds for a 220-pound starting weight.

Weeks 13 to 16 (1.7 mg). Weight loss continues at roughly 0.5 to 1.5 pounds per week for most patients. By week 16 the average STEP 1 patient had lost about 9% of body weight. Side effects are typically mild at this stage if titration was tolerated.

Weeks 17 to 28 (2.4 mg maintenance). At full dose, weight loss continues at a slower pace, averaging 0.3 to 0.8 pounds per week. By week 28, average STEP 1 weight loss was approximately 11.5%.

Weeks 29 to 68. Weight loss decelerates as patients approach their individual setpoint. The 68-week endpoint of STEP 1 showed an average loss of 14.9% from baseline. About one in three patients lost more than 20%. About 7% saw less than 5% loss and were classified as non-responders.

Beyond week 68. The STEP 5 trial extended treatment to 104 weeks and showed continued weight maintenance with modest additional loss (Garvey et al., Nat Med 2022). Patients who stopped treatment at any point regained roughly two-thirds of lost weight within a year (STEP 4, Rubino et al., JAMA 2021).

The STEP 1 trial: published weight-loss curves

STEP 1 (Wilding et al., NEJM 2021) is the foundational trial for Wegovy in obesity. Key numbers from the trial:

The trial enrolled 1,961 adults with BMI 30+ (or BMI 27+ with at least one weight-related condition) and no diabetes. Both groups received counseling on diet and physical activity.

The shape of the curve matters. Weight loss is fastest in the first 20 weeks, plateaus gradually between weeks 28 and 52, and reaches near-asymptote by week 68. That pattern matches what most clinicians see in practice.

Why some patients respond faster than others

Individual variation in Wegovy response is large. Reasons include:

• Baseline insulin resistance. Patients with prediabetes or type 2 diabetes often see slightly slower initial weight loss but similar long-term outcomes.
• Genetics of GLP-1 signaling. Variants in the GLP-1 receptor gene change response intensity (Yaghootkar et al., Nat Metab 2020).
• Diet quality during titration. Patients who pair Wegovy with a higher-protein, lower-refined-carb diet tend to lose more in the first 12 weeks.
• Sleep. Sleep restriction increases hunger hormones and blunts GLP-1 response (Spiegel et al., Ann Intern Med 2004). Patients sleeping under 6 hours per night tend to lose less.
• Exercise level. Resistance training preserves lean mass and improves the body-composition outcome at any given weight loss.
• Adherence. Missing doses or stretching the dosing interval to 10 to 14 days reduces effective drug exposure.

A patient losing 1.5 pounds per week in month 2 and a patient losing 0.5 pounds per week in month 2 can both end up with similar 14% loss at 68 weeks. The early curve does not perfectly predict the long-term outcome.

The 16-week response check

The Wegovy prescribing information recommends a check at week 16 (after 12 weeks at the 1.0 mg dose or higher). The threshold is 5% body-weight loss.

Patients who have lost less than 5% by week 16 to 20 at maintenance dose are classified as poor responders. Roughly 13 to 17% of patients fall into this group. Options include:

• Continue treatment for an additional 8 to 12 weeks. Some late-blooming patients catch up.
• Switch to tirzepatide (Zepbound), which produces larger average weight loss (Jastreboff et al., NEJM 2022).
• Investigate competing medications or interfering medications (steroids, certain antipsychotics, beta-blockers).
• Reassess diet, sleep, and exercise inputs.

Strong responders often hit 8 to 10% loss by week 16, which predicts 18 to 25% loss by week 68.

When Wegovy is "not working" yet vs not working at all

A patient at week 4 saying "Wegovy isn't working" is usually too early. The starter dose alone rarely produces dramatic weight loss. The same statement at week 20 at 2.4 mg with under 3% loss is a different problem.

Signs Wegovy is working but slowly:

• Reduced appetite and earlier satiety
• Smaller portion sizes without effort
• Less interest in food in general
• Steady but slow scale movement (0.5 to 1 pound per week)
• Improvements in waist circumference even when scale is sticky

Signs Wegovy may not be working:

• No change in appetite at all after 8 weeks at any dose
• No weight loss at week 16 to 20 at 1.7 mg or higher
• Worsening side effects without therapeutic benefit
• Compensatory eating behavior (graze eating, late-night eating) overwhelming the appetite suppression

The right move at the 16 to 20 week check is a clinical conversation with the prescribing provider, not a drug-store decision.

How food, sleep, and exercise change the timeline

Food. Wegovy reduces hunger but does not pick foods for you. Patients eating mostly highly processed snacks during the first 12 weeks usually lose less than patients eating whole foods, even with similar calorie intake. Protein at every meal (roughly 0.7 to 1.0 g per pound of goal body weight) preserves lean mass and improves satiety.

Sleep. Six or fewer hours per night raises ghrelin (hunger hormone) and lowers leptin (satiety hormone), partially fighting the GLP-1 effect. Patients who improve sleep from under 6 to over 7 hours often see weight loss accelerate within 2 to 3 weeks of the change.

Exercise. Cardiovascular exercise produces small additive weight loss. Resistance training does something different, it preserves muscle mass during caloric deficit. Patients lifting 2 to 3 times per week through a Wegovy course end up with better body composition at any given weight loss percentage.

Hydration and fiber. GI side effects often track dehydration and low fiber intake. Aiming for 64+ oz of water and 25 to 35 g of fiber per day reduces the constipation-nausea cycle that interrupts dose escalation in some patients.

FAQ

How fast does Wegovy start working after the first injection? Pharmacologically within hours. Patients usually notice reduced appetite by day 1 to 3, and weight loss of 0 to 2 pounds in week 1. Visible body change typically appears between week 4 and 8.

Why am I not losing weight on Wegovy? Most often the dose is still in titration. The 0.25 mg and 0.5 mg doses produce minimal weight loss. If you are at 1.7 mg or higher and not losing, consider sleep, alcohol, undiagnosed thyroid issues, interfering medications, or non-response. Talk with your provider.

When should I see weight loss on Wegovy? Most patients see scale movement by week 4 to 8 and visible body changes by week 12. The STEP 1 trial showed average loss of 5.9% by week 12 (Wilding et al., NEJM 2021).

How much weight will I lose in the first month of Wegovy? Typical first-month loss is 3 to 6 pounds, or 1 to 3% of starting body weight. The first month is on the 0.25 mg starter dose, which produces modest results.

Why is Wegovy weight loss slow at first? Because the starter dose is 0.25 mg, less than one-tenth of the maintenance dose. Titration is required to reduce nausea and vomiting. Real weight-loss acceleration usually starts after week 8 to 12.

How fast does Wegovy work compared with Zepbound? Both work on similar timelines, but Zepbound (tirzepatide) typically produces larger average weight loss. SURMOUNT-1 showed 20.9% mean loss at 72 weeks at the 15 mg dose (Jastreboff et al., NEJM 2022) versus 14.9% for Wegovy at 68 weeks.

Can I speed up Wegovy weight loss? You can support it with adequate protein, 7+ hours of sleep, resistance training 2 to 3 times per week, and hydration. Skipping titration steps or doubling doses does not speed weight loss and increases side effects.

Will Wegovy still work if I miss a dose? A single missed dose can be taken within 2 days of the scheduled day. If more than 2 days have passed, skip and resume on the regular weekly schedule. Repeated missed doses extend the titration timeline and reduce overall effectiveness.

Does Wegovy work for everyone? No. Roughly 86 to 90% of patients lose at least 5% of body weight by week 68. About 10 to 14% are non-responders. Reasons range from genetic variation in GLP-1 signaling to dietary patterns to interfering medications.

How long does it take to feel full on Wegovy? Most patients feel earlier satiety within 1 to 2 weeks of the first dose. The effect deepens with each escalation. By the 1.0 mg dose, many patients describe small portions feeling like full meals.

Is week 1 weight loss real fat loss? Mostly no. Week 1 weight changes are largely water and reduced food residence in the gut. Real fat loss accumulates from week 3 onward and accelerates after week 8.

Does Wegovy stop working over time? Effectiveness can plateau as patients approach their individual setpoint, usually after week 28. STEP 5 data through 104 weeks shows continued maintenance with modest additional loss (Garvey et al., Nat Med 2022). True tachyphylaxis (the drug losing effect) is uncommon.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5. Nat Med. 2022;28(10):2083-2091.
4. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: STEP 4. JAMA. 2021;325(14):1414-1425.
5. Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380.
6. Yaghootkar H, et al. Genetic studies of body mass index yield new insights for obesity biology. Nat Metab. 2020.
7. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846-850.
8. Novo Nordisk. Wegovy Prescribing Information. Revised 2024.
9. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. June 2021.
10. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
11. American Heart Association. Scientific Statement on Obesity and Cardiovascular Disease. Circulation. 2021.
12. NIDDK. Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.